Karyopharm Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
11/08/2025 14:31
Karyopharm Therapeutics Inc KPTI.OQ reported a quarterly adjusted loss of $4.32 per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of $2.25. The mean expectation of seven analysts for the quarter was for a loss of $4.10 per share. Wall Street expected results to range from $-4.95 to $-3.47 per share. Revenue fell 11.4% to $37.93 million from a year ago; analysts expected $36.94 million. Karyopharm Therapeutics Inc's reported EPS for the quarter was a loss of $4.32. The company reported a quarterly loss of $37.25 million. Karyopharm Therapeutics Inc shares had fallen by 8.6% this quarter and lost 61.2% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had risen by about 0.6% in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" Wall Street's median 12-month price target for Karyopharm Therapeutics Inc is $15.00, about 73.7% above its last closing price of $3.94 This summary was machine generated from LSEG data August 11 at 01:31 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Jun. 30 2025 | -4.10 | -4.32 | Missed |
| Mar. 31 2025 | -4.18 | -2.77 | Beat |
| Dec. 31 2024 | -3.92 | -3.60 | Beat |
| Sep. 30 2024 | -3.94 | -3.90 | Beat |
Recent news on Karyopharm Therapeutics
See all newsBrief: Karyopharm Therapeutics - Enters Forbearance Agreement And Waiver On Sept 10, 2026 - SEC Filing
Brief: Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Karyopharm Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Karyopharm Q2 revenue falls as license revenue drops; expects funds to last into September
Karyopharm Therapeutics Inc. expected to post a loss of $1.28 a share - Earnings Preview